Early-stage fundraising in Europe increasingly relies on instruments that defer valuation: the SAFE (Simple Agreement for Future Equity) and the convertible loan (also called a convertible note). Both allow investors to provide capital today in exchange for equity at a future financing round, but they differ in critical ways that affect legal classification, tax treatment, creditor rights, and investor leverage. Understanding those differences is essential for founders and investors operating across European jurisdictions.
Origins and Conceptual Architecture
The SAFE was developed by Y Combinator in 2013 as a stripped-down alternative to the convertible note, designed specifically to remove the friction of interest accrual, maturity dates, and debt mechanics. A SAFE is not a loan; it is a contractual right to receive equity upon a triggering event, typically a priced funding round, an acquisition, or a liquidity event. The instrument was conceived in a US legal environment where Delaware corporate law provides a flexible framework for issuing such rights.
In Europe, the SAFE has gained traction since approximately 2016–2018, especially in the UK and among continental founders who had exposure to US accelerator programs. Several European venture ecosystems, including those in France, the Netherlands, Germany, and Belgium, have seen SAFEs deployed, but they require careful adaptation to local corporate law. The convertible loan, by contrast, has deep roots in European commercial and banking practice and fits more naturally into the legal frameworks of most EU member states.
Legal Classification: Debt vs. Quasi-Equity
The most consequential structural difference is that a convertible loan is a debt instrument. The investor is a creditor until conversion occurs. This creates several implications. First, if the company becomes insolvent before conversion, the convertible loan holder ranks ahead of equity holders in the waterfall, though typically behind secured and senior creditors. Second, in most European jurisdictions, loans must comply with regulations on interest-bearing instruments, and in some countries — notably Belgium and Germany — thin capitalisation rules, minimum interest requirements, or usury regulations may apply.
A SAFE, by contrast, has no debt character. It does not accrue interest, carries no maturity date, and does not give the holder creditor rights. In insolvency, a SAFE holder is generally treated as an equity holder and recovers only after all creditors are paid. This fundamentally changes the risk profile: SAFE investors accept more downside in exchange for simpler documentation and potentially more favourable conversion mechanics.
In several European jurisdictions, this classification also triggers regulatory implications. In France, for instance, instruments that share economic characteristics of securities may require compliance with prospectus rules if distributed broadly. In Germany, the characterisation of a SAFE as a financial instrument under MiFID II could apply if the instrument is offered to multiple investors in a structured manner. Founders and counsel should therefore assess whether a SAFE in a particular jurisdiction is being offered in a manner that triggers securities law obligations.
Conversion Mechanics: Discount and Cap
Both instruments typically include a valuation cap and/or a conversion discount. The cap sets a maximum pre-money valuation at which the instrument converts, protecting early investors from excessive dilution if the company raises at a very high valuation. The discount provides that the instrument converts at a percentage below the price paid by new investors, compensating for early-stage risk.
In convertible loans, the conversion calculation is typically specified in detail in the loan agreement, and the mechanics must be consistent with corporate law requirements in the relevant jurisdiction. Many European jurisdictions require that share issuances comply with pre-emption rights procedures, board or shareholder approvals, and, in certain cases, notarial formalities. In France and Belgium, issuances of shares upon conversion may require an extraordinary shareholders’ meeting or the prior delegation of authority to the board.
SAFE conversions face the same corporate law constraints, but since SAFEs are often designed by counsel familiar with US practice, there is a risk that the conversion mechanics assume a legal flexibility that does not exist in the target jurisdiction. Practitioners drafting SAFEs for European companies must verify that the automatic conversion mechanism is enforceable as written under local law, particularly in jurisdictions where equity issuances are subject to mandatory procedural requirements.
Interest Accrual and Tax Treatment
One of the frequently overlooked dimensions of the SAFE versus convertible loan comparison is tax. In most European jurisdictions, a convertible loan generates a tax deduction for the company on interest paid or accrued, even if no cash is exchanged, because the interest is treated as a finance cost under standard accounting rules. This can be beneficial for profitable companies but is largely irrelevant for pre-revenue startups that are already in a tax loss position.
For the investor, the interest on a convertible loan is taxable income in most EU jurisdictions, which can be administratively inconvenient and may reduce net returns if the loan never converts. Upon conversion, the gain may be treated as a capital gain or as income depending on the holding period, the investor’s legal status (individual vs. fund), and the applicable double tax treaty. In Belgium, the distinction matters because capital gains on shares held by individuals are generally exempt, while interest income is subject to withholding tax.
SAFEs typically generate no interest and therefore no periodic tax event for either party. The economic return materialises entirely at conversion or on a liquidity event, which in most European systems will be treated as a capital gain if the holding period requirements are satisfied. This simplicity makes SAFEs attractive from a tax administration standpoint, though the exact treatment varies and should be confirmed with local counsel.
Maturity and Default Scenarios
A defining feature of the convertible loan is its maturity date. If a qualifying financing round has not occurred by maturity, the investor typically has the right to demand repayment, convert at a pre-agreed formula, or negotiate an extension. This creates real leverage: an investor holding a convertible note maturing at an inconvenient time can significantly influence a company’s strategic decisions, including whether to accept a suboptimal investment round or pursue an acquisition.
This leverage is absent from a SAFE. There is no maturity date, and the company has no legal obligation to return the capital unless a triggering event occurs. For founders, this is clearly advantageous. For investors, the tradeoff is the absence of the downside protection that debt provides. An investor in a SAFE who finds that the company is operating but not raising a new priced round may be in a structurally weak position, particularly if the founders are not incentivised to trigger conversion.
Some European practitioners have attempted to address this by including SAFE variants with sunset clauses or mandatory conversion triggers, but these modifications often reintroduce debt-like features and require careful drafting to ensure they do not inadvertently reclassify the instrument under local law.
Governance Rights During the Pre-Conversion Period
Neither a SAFE nor a convertible loan typically grants governance rights before conversion. The investor does not hold shares, so voting rights, information rights, and board observation rights must be separately negotiated. In practice, convertible loans in Europe frequently include covenants and information rights that give the lender contractual protections, including the right to access financial statements, restrictions on incurring additional indebtedness, and negative covenants on material changes to the business.
SAFEs, being lighter instruments, often include fewer protective covenants. Investors who are accustomed to convertible loan protections and are considering using a SAFE for the first time should be aware that they may be giving up contractual visibility into the company’s affairs. This matters more for angel investors and family offices making concentrated bets than for institutional seed funds that invest in large portfolios and manage through post-conversion board seats.
Jurisdiction-Specific Considerations
Several European jurisdictions have developed their own standardised early-stage investment instruments. France introduced the BSA Air (Bon de Souscription d’Actions) as a warrant-based instrument that functions similarly to a SAFE but fits within the French corporate law framework. The UK has developed its own SEIS and EIS-compatible convertible instruments, and the British Business Bank has worked with the ecosystem to standardise convertible loan terms for tax-advantaged investing.
In Germany, the SAFE remains relatively less common than in the UK or France, partly because the GmbH (the standard limited liability company form) imposes stricter requirements on equity issuances and share register formalities. Converting a SAFE into shares of a GmbH typically requires notarial involvement, which increases cost and time. Some German startups address this by converting to a GmbH & Co. KG structure or by incorporating in a jurisdiction perceived as more flexible, such as the Netherlands or Estonia.
The Netherlands has seen growing adoption of both instruments, with Dutch startups often favouring a convertible loan documented under Dutch law but referencing conversion mechanics drawn from US practice. Belgium similarly sees a mix, with some practitioners adapting the American SAFE structure and others relying on established convertible bond frameworks under the Belgian Companies and Associations Code.
Strategic Considerations for Founders and Investors
Founders should recognise that the choice between a SAFE and a convertible loan is not merely a legal formality but a negotiation outcome. Sophisticated investors may prefer convertible loans because of the creditor protection, the maturity leverage, and the greater clarity around interest economics. Founders, on the other hand, generally prefer SAFEs for their simplicity, the absence of a debt overhang, and the removal of maturity date pressure.
Where both parties want to proceed quickly without extensive negotiation, a standardised instrument — whether a SAFE or a template convertible loan from a recognised ecosystem body — will often serve better than a heavily negotiated bespoke document. However, the trade-off is that standardised templates may not adequately address jurisdiction-specific requirements or the specific risk profile of the transaction.
Investors in cross-border transactions, particularly those investing through a Luxembourg or Dutch holding vehicle into an operating company in another EU member state, should consider the interaction between the tax treatment at the holding vehicle level and the tax treatment of the instrument in the operating company’s jurisdiction. Double tax treaty analysis, withholding tax on interest, and thin capitalisation rules can materially affect the economics of a convertible loan that involves an intra-group element.
Conclusion
The SAFE and the convertible loan serve the same commercial purpose but operate in very different legal registers. In the European context, the convertible loan remains the more structurally predictable instrument because it fits within established debt frameworks. The SAFE offers greater simplicity and removes maturity risk but requires careful adaptation to local corporate and securities law and may offer fewer protections to investors who value creditor rights. For any early-stage financing, founders and investors are well-advised to engage counsel familiar with both US financing practices and the specific corporate law of the relevant jurisdiction before selecting and documenting the instrument.